Literature DB >> 8864420

Intestinal phase of human antro-pyloro-duodenal motility: cholinergic and CCK-mediated regulation.

M Katschinski1, J Schirra, C Begliner, S Langbein, U Wank, M D'Amato, R Arnold.   

Abstract

In this study the muscarinic receptor antagonist atropine and the cholecystokinin (CCK)-A receptor antagonist loxiglumide were used to investigate the relative importance of cholinergic and CCK-mediated regulation of intestinal phase antro-pyloro-duodenal motility. Plasma levels of gastrointestinal hormones [pancreatic polypeptide (PP), gastrin, CCK] were concomitantly determined to estimate biological potency of the doses of the receptor antagonists. In eight healthy male volunteers, a 30-min basal interdigestive period was followed by duodenal perfusion of a mixed liquid meal for 150 min at 1.6 kcal min-1 against a background of saline or atropine (5 micrograms kg-1 h-1) or loxiglumide (10 mg kg-1 h-1). Antropyloro-duodenal motility was continuously monitored with a sleeve straddling the pylorus. Against a background of saline, duodenal nutrients persistently stimulated isolated pyloric pressure waves. After 60 min, the initially low antral and duodenal contraction rates increased. In the fed state, atropine reduced total number of antral contractions and integrated motility index by 73% (P < 0.01) and 76% (P < 0.005), total number of pyloric contractions and integrated motility index by 43% and 50% (P < 0.05) with inhibition increasing over time. It did not alter duodenal contraction frequency but diminished duodenal motility index by 39% (P < 0.05) owing to a reduction in amplitude and duration of contractions. Loxiglumide decreased total numbers of antral, pyloric and duodenal contractions by 44% (P < 0.05), 74% (P < 0.005) and 41% (P < 0.005) respectively. It reduced cumulative antral, pyloric and duodenal motility indexes by 60% (P < 0.01), 80% (P < 0.01) and 61% (P < 0.05) respectively. Atropine fully abolished PP release to duodenal nutrients whereas loxiglumide reduced it by 60% (P < 0.05). Both atropine and loxiglumide enhanced gastrin release whereas only loxiglumide markedly stimulated CCK release. We conclude that both cholinergic input and endogenous CCK are major stimulatory regulators of antro-pyloroduodenal motility in the intestinal phase. There appears to be a regional heterogeneity of cholinergic and CCK control. Cholinergic input predominates in the antrum. Both systems are equipotent at the pylorus. CCK predominates in the duodenum. We suggest that CCK primarily interacts with receptors on cholinergic neurons in the antropyloric region and primarily affects smooth muscle receptors in the duodenum.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8864420     DOI: 10.1046/j.1365-2362.1996.1790522.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  8 in total

1.  Effect of intravenous amino acids on interdigestive antroduodenal motility and small bowel transit time.

Authors:  H A Gielkens; A van den Biggelaar; J Vecht; W Onkenhout; C B Lamers; A A Masclee
Journal:  Gut       Date:  1999-02       Impact factor: 23.059

2.  Modulation of individual components of gastric motor response to duodenal glucose.

Authors:  Adam M Deane; Laura K Besanko; Carly M Burgstad; Marianne J Chapman; Michael Horowitz; Robert J L Fraser
Journal:  World J Gastroenterol       Date:  2013-09-21       Impact factor: 5.742

3.  Human duodenal motor activity in response to acid and different nutrients.

Authors:  M P Schwartz; M Samsom; A J Smout
Journal:  Dig Dis Sci       Date:  2001-07       Impact factor: 3.199

Review 4.  Ghrelin, CCK, GLP-1, and PYY(3-36): Secretory Controls and Physiological Roles in Eating and Glycemia in Health, Obesity, and After RYGB.

Authors:  Robert E Steinert; Christine Feinle-Bisset; Lori Asarian; Michael Horowitz; Christoph Beglinger; Nori Geary
Journal:  Physiol Rev       Date:  2017-01       Impact factor: 37.312

5.  Effects of glucagon-like peptide-1(7-36)amide on antro-pyloro-duodenal motility in the interdigestive state and with duodenal lipid perfusion in humans.

Authors:  J Schirra; P Houck; U Wank; R Arnold; B Göke; M Katschinski
Journal:  Gut       Date:  2000-05       Impact factor: 23.059

6.  Effects of Intraduodenal Infusion of the Bitter Tastant, Quinine, on Antropyloroduodenal Motility, Plasma Cholecystokinin, and Energy Intake in Healthy Men.

Authors:  Vida Bitarafan; Penelope C E Fitzgerald; Tanya J Little; Wolfgang Meyerhof; Tongzhi Wu; Michael Horowitz; Christine Feinle-Bisset
Journal:  J Neurogastroenterol Motil       Date:  2019-07-01       Impact factor: 4.924

7.  Tonic and phasic pyloric activity in response to CCK-octapeptide.

Authors:  Frank K Friedenberg; Joshua Desipio; Annapurna Korimilli; Matthew Bohning; Eva Sum; Henry P Parkman; Joel E Richter; Robert S Fisher
Journal:  Dig Dis Sci       Date:  2008-02-13       Impact factor: 3.199

8.  Increased cholinergic contractions of jejunal smooth muscle caused by a high cholesterol diet are prevented by the 5-HT4 agonist--tegaserod.

Authors:  Ronald Mathison; Eldon Shaffer
Journal:  BMC Gastroenterol       Date:  2006-02-23       Impact factor: 3.067

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.